,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['mbc', 'breast']
safety f/u of destiny-breast 03. mdn duration of rx:16.1months for t-dxd vs. 6.9 months for t-dm1 14.3% discontinuation rate with t-dxd (ild common)vs. 7.3% w/ t-dm1 n/v and alopecia w/ t-dxd 10.9% incidence of ild. 0.8% grade 3 ild. no gr 4 or 5 #mbc #asco2022 
Breast Medical Oncologist @RutgersCancer @Rutgers and @RWJMS wife/mom/baker/world traveler #bcsm